沫舒坦治疗重型颅脑损伤后合并肺部感染的研究

摘要]目的：探讨沫舒坦治疗重型颅脑损伤伴肺炎患者的疗效及不良反应。方法：GCS评分 3～8分的病例76例随机分两组，即观察组予沐舒坦静滴 雾化吸入连续14天；对照组未应用沫舒坦。结果：观察组：肺炎控制36例，时间(8.0±3.7)天；对照组：肺炎控制30例，时间(11.3±4.9)天，比较两组疗效及控制时间均有统计学差异(P<0.05)。无显著不良反应。结论：本组病例应用沫舒坦治疗能提高感染控制率，促进神经功能恢复，缩短治疗时间，值得临床推广应用。

Study ambroxyl treatment patients with pulmonary infection after severe craniocerebral injury

Abstract: Objective To explore the clinical efficacy and side effects of ambroxyl pneumonia after severe craniocerebral injury .Methods The admission GCS 3 ~ 8 of the pneumonia after severe brain injury in 76 patients were randomly divided into experimental group and contrast group. The experiment group were treated with ambroxol treatment: given 30 mg, intravenous drip, 3 times / day, while the 15 mg inhalation, 2 times / day, consecutive 14 days; Contrast group for the same injury in 38 patients without the use of ambroxyl treatment.Results The patients in the experimental group had 36 cases of infection control, infection control time averaged (8.0±3.7) d; Contrast group had 30 cases of infection control, infection control time averaged (11.3±4.9) d, was analyzed using the SPSS11.5 statistical treatment of experimental group, contrast group, the effective rate of the difference was statistically significant (P< 0.05); the average time and control infection was significantly shorter than the contrast group (P< 0.05). No obvious adverse effects during treatment.Conclusions Application of ambroxyl clinical treatment can promote the recovery of patients with pneumonia after severe craniocerebral injury, shorten the treatment cycle, with no obvious side effects.